Wildflower Brands Inc. (CSE:SUN, OTC:WLDFF) (the “Company”) is pleased to announce revenue for the fiscal year ending June 30, 2019 of $7.1M – a 400% increase over revenues of $1.4M in 2018.  The Company began aggressively marketing its CBD Wellness products during the fiscal year, culminating with the launch of its products in June 2019 at Dillard’s, an American department retail chain with over 290 stores in 29 states.

Highlights for the year ending June 30, 2019 (with comparisons to the prior year except as otherwise noted) include the following:


  • Sales of $7,085,223 (2018: $1,408,114), including licensing fees from sales through our partner in the Washington State I-502 market, US nationwide e-commerce sales, nationwide US wholesale sales and from the sales in California State’s regulated market through the licenses held there;
  • Cost of goods sold of $3,927,086 (2018: $915,997) related to the cost of the products and packaging sold during the year;
  • Wages and benefits of $1,515,177 (2018: $175,669) related to wages and related benefits paid to employees;
  • Consulting fees and management fees of $978,018 (2018: $473,735) related to fees paid to the Company’s CEO, CFO, COO and board of directors, as well as individuals providing business consulting services;
  • Advertising and marketing costs of $384,616 (2018: $313,068) related to advertising and marketing campaigns for the Company’s cannabis products, as well as funds expended toward the branding of the retail locations in Manhattan under its Retail Worx agreement;
  • Investor relations and shareholder communications of $691,532 (2018: $393,420) related to fees paid to investor relations personnel and costs associated with public relations;
  • Legal fees of $626,213 (2018: $59,015) related to general corporate matters and acquisitions, including the acquisition of City Cannabis Corp.;
  • Bad debt expense of $1,198,808 (2018: $Nil) to recognize an allowance for doubtful accounts related to trade receivables;
  • General office and miscellaneous expenses of $430,393 (2018: $166,621) related to office supplies and incidental expenditures for the Company’s Vancouver-based office, Washington State subsidiary office, and Californian subsidiary office;
  • Share-based payment expense of $331,222 (2018: $1,924,750) related to the fair value of incentive stock options granted during the year;
  • Rent of $331,269 (2018: $101,191) related to office space in Vancouver and Washington State;
  • Travel and accommodation of $182,336 (2018: $117,342) related to travel for business activities;
  • Write off of loan receivable of $179,867 (2018: $173,236) as the Company deemed the amounts to be unrecoverable;
  • Interest expense of $901,406 (2018: $129,770) related to the interest accrued on the loans payable, promissory notes and convertible debentures issued during the period;
  • Gain on agreement revision of $810,262 (2018: $Nil) representing the difference in book value of the property and equipment deemed to have been disposed of under an industrial lease agreement and the present value of the lease obligations for the same property; and
  • Exchange difference of $321,616 (2018: $454,657) related to translating the transactions of the Company’s foreign subsidiaries with a functional currency other than the Canadian dollar.

ABOUT WILDFLOWER BRANDS

The Company is a Vancouver-based pioneer in the cannabis industry that develops, designs and operates brands throughout North America. Our brands work together to make Wildflower a leader in cannabis innovation throughout the globe. The Company operates British Columbia’s largest retail cannabis chain under the brand City Cannabis Co.

On Behalf of the Board of Directors

“William MacLean”
William MacLean
Director and CEO

The Canadian Securities Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release.

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Click here to connect with Wildflower Brands Inc. (CSE:SUN, OTCQB:WLDFF, FWB:RSP) for an Investor Presentation.

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less